Singapore markets open in 4 hours 17 minutes
  • Straits Times Index

    3,283.35
    -11.51 (-0.35%)
     
  • S&P 500

    4,363.87
    -34.07 (-0.77%)
     
  • Dow

    34,020.47
    -244.90 (-0.71%)
     
  • Nasdaq

    13,698.62
    -70.30 (-0.51%)
     
  • BTC-USD

    36,435.51
    +1,227.14 (+3.49%)
     
  • CMC Crypto 200

    829.97
    +19.37 (+2.39%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Gold

    1,838.90
    +7.10 (+0.39%)
     
  • Crude Oil

    83.60
    -1.54 (-1.81%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Nikkei

    27,588.37
    +66.11 (+0.24%)
     
  • Hang Seng

    24,656.46
    -309.09 (-1.24%)
     
  • FTSE Bursa Malaysia

    1,521.86
    -5.20 (-0.34%)
     
  • Jakarta Composite Index

    6,655.17
    -71.21 (-1.06%)
     
  • PSE Index

    7,252.64
    -40.88 (-0.56%)
     

Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • RUBY

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 10:55 a.m. EST.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, VP Investor Relations
elhan.webb@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting